First Time Loading...

Vita 34 AG
XETRA:V3V

Watchlist Manager
Vita 34 AG Logo
Vita 34 AG
XETRA:V3V
Watchlist
Price: 4.66 EUR 3.1%
Updated: Mar 28, 2024

Intrinsic Value

Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. [ Read More ]

The intrinsic value of one V3V stock under the Base Case scenario is 5.67 EUR. Compared to the current market price of 4.66 EUR, Vita 34 AG is Undervalued by 18%.

Key Points:
V3V Intrinsic Value
Base Case
5.67 EUR
Undervaluation 18%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Vita 34 AG

Backtest V3V Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling V3V stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Vita 34 AG

Current Assets 34.3m
Cash & Short-Term Investments 10.4m
Receivables 18.8m
Other Current Assets 5.1m
Non-Current Assets 114.7m
Long-Term Investments 1.5m
PP&E 36.4m
Intangibles 56.4m
Other Non-Current Assets 20.5m
Current Liabilities 50.6m
Accounts Payable 7.9m
Other Current Liabilities 42.7m
Non-Current Liabilities 86.3m
Long-Term Debt 11.9m
Other Non-Current Liabilities 74.4m
Efficiency

Earnings Waterfall
Vita 34 AG

Revenue
74.9m EUR
Cost of Revenue
-64.2m EUR
Gross Profit
10.7m EUR
Operating Expenses
-32.8m EUR
Operating Income
-22.1m EUR
Other Expenses
-2.8m EUR
Net Income
-24.9m EUR

Free Cash Flow Analysis
Vita 34 AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

V3V Profitability Score
Profitability Due Diligence

Vita 34 AG's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Positive Revenue Growth Forecast
Negative Free Cash Flow
31/100
Profitability
Score

Vita 34 AG's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

V3V Solvency Score
Solvency Due Diligence

Vita 34 AG's solvency score is 27/100. The higher the solvency score, the more solvent the company is.

Positive Net Debt
Long-Term Solvency
Low D/E
Short-Term Solvency
27/100
Solvency
Score

Vita 34 AG's solvency score is 27/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

V3V Price Targets Summary
Vita 34 AG

Wall Street analysts forecast V3V stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for V3V is 5.56 EUR with a low forecast of 5.35 EUR and a high forecast of 5.88 EUR.

Lowest
Price Target
5.35 EUR
15% Upside
Average
Price Target
5.56 EUR
19% Upside
Highest
Price Target
5.88 EUR
26% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

V3V Price
Vita 34 AG

1M 1M
-3%
6M 6M
+2%
1Y 1Y
-24%
3Y 3Y
-69%
5Y 5Y
-66%
10Y 10Y
-5%
Annual Price Range
4.66
52w Low
4.04
52w High
7.24
Price Metrics
Average Annual Return -8.93%
Standard Deviation of Annual Returns 28.58%
Max Drawdown -77%
Shares Statistics
Market Capitalization 73.8m EUR
Shares Outstanding 16 170 000
Percentage of Shares Shorted
N/A

V3V Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Vita 34 AG Logo
Vita 34 AG

Country

Germany

Industry

Health Care

Market Cap

73.8m EUR

Dividend Yield

0%

Description

Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. The company is headquartered in Leipzig, Sachsen and currently employs 124 full-time employees. The company went IPO on 2007-03-27. The firm is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The firm acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The firm operates in Germany, Spain and Denmark.

Contact

SACHSEN
Leipzig
Deutscher Platz 5a
+49341487920.0
https://www.vita34.de/

IPO

2007-03-27

Employees

124

Officers

Chairman of the Management Board & CEO
Mr. Jakub Julian Baran
Vice President of the Management Board & Chief Commercial Officer
Mr. Tomasz Franciszek Baran
Managing Director of Secuvita
Santiago Luengo

See Also

Discover More
What is the Intrinsic Value of one V3V stock?

The intrinsic value of one V3V stock under the Base Case scenario is 5.67 EUR.

Is V3V stock undervalued or overvalued?

Compared to the current market price of 4.66 EUR, Vita 34 AG is Undervalued by 18%.